Scientific Programme - Topics to be covered
- Preclinical research on the mechanisms of malignant transformation of hepatic cells and of cell-to-cell interactions
- Basic and translational research on the biology, genetics, and immunology of HCC and CCA
- New developments in HCC and CCA management, including new targeted agents and recent data and implications for immunotherapy of HCC and CCA
- Personalized medicine
- The new challenge of microbiota and liver cancer
- Novel biomarker concepts in HCC and CCA
- Discussions on clinical trials between academia, pharma and regulatory agencies
Find out more about EASL. Also discover EASL’s LinkedIn page for the latest news.
